MAP

2.94%

17.5¢ microba life sciences limited

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-5

First 5 Last

Share
Profile

Follow
Lucretious

5,920 Posts.

1830

21/07/22

12:13

Post #: 62650369
Share

Originally posted by triage: ↑

Agree, impressive. I do have one concern and a couple of queries.

At first blush I worry that Luke Reid is being a tad cocky with this comment: "In FY23 we will advance into the clinic with our lead IBD asset MAP315 which we expect to generate significant value for shareholders".

I seem to recall seeing claims that only about 6% of products that make it through phase 1 clinical trial go onto being commercialised (and from memory about 40% of phase 2 and 80% of phase 3 end up making it to market). MAP315 is not even at the start line for a phase 1 trial. Unless LR knows something that he is not telling us I think "hope" rather than "expect" would have been closer to reality.

A couple of questions: I wonder how much of that revenue figure for Q4FY22 was from sale of testing services and how much was from sales to research clients. It seems to me that the the testing services are scalable but the research clients not so much.

Also given that the new distributorship arrangements were only bedded down at the end of the June quarter I wonder how much of a revenue boost is expected in coming quarters from the new distributors and the new product. I can find no guidance at all in either the quarterly or the presentation deck let alone the sort of estimates that Lefevre kindly shared a while back.

And finally, an observation: for every set of test data they get approval to keep and use not only do they get more revenue dollars they also get more grist for their AI. I follow a few companies that claim to be trying to use big data to disrupt normal order. Most likely some are pretenders and some will be failures. But Microba seems as well placed as any with its microbiome analysis skills and its growing dataset of both health and bugs.

Expand

A good report and lots going on and headed in the right direction and awash with cash in difficult macro times. I am in this because a) I like the area/field they are in which is trying to break new ground in medical science and b) Ginkgo Bioworks backed them and I hold Ginkgo, who appear to me to be playing in the biotech field by seed funding several start ups or new to listing companies exploring differing areas in this field

Accumulating

MAP Price at posting: 29.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add MAP (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change 0.005(2.94%)		Mkt cap ! $78.37M

Open	High	Low	Value	Volume
18.0¢	18.0¢	17.5¢	$10.77K	60.02K

Buyers (Bids)

No.	Vol.	Price($)
1	256560	17.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	247020	2

View Market Depth

No.	Vol.	Price($)
1	256560	0.175
1	36318	0.170
2	5060	0.165
2	12437	0.160
2	12481	0.155

Price($)	Vol.	No.
0.180	35909	1
0.185	38800	1
0.190	34200	1
0.195	280479	3
0.200	227265	5

Last trade - 15.32pm 27/09/2024 (20 minute delay)

MAP (ASX) Chart

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-5

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-5

Top Stories

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News